RTW Biotech Opportunities (LON:RTW - Get Free Report)'s stock price traded up 1.2% during mid-day trading on Wednesday . The stock traded as high as GBX 1.26 ($0.02) and last traded at GBX 1.26 ($0.02). 495,137 shares changed hands during trading, an increase of 129% from the average session volume of 215,884 shares. The stock had previously closed at GBX 1.25 ($0.02).
RTW Biotech Opportunities Stock Down 1.6 %
The company has a market capitalization of £416.53 million, a PE ratio of 2.96 and a beta of 0.60. The business has a 50 day simple moving average of GBX 1.34 and a 200 day simple moving average of GBX 1.44.
RTW Biotech Opportunities Company Profile
(
Get Free Report)
RTW Biotech Opportunities Ltd (LSE: RTW or RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
Recommended Stories
Before you consider RTW Biotech Opportunities, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RTW Biotech Opportunities wasn't on the list.
While RTW Biotech Opportunities currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
